Analyzing Eliem Therapeutics (NASDAQ:ELYM) and Graybug Vision (NASDAQ:GRAY)

Insider & Institutional Ownership

69.8% of Eliem Therapeutics shares are held by institutional investors. Comparatively, 49.9% of Graybug Vision shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by company insiders. Comparatively, 7.9% of Graybug Vision shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Eliem Therapeutics has a beta of -0.39, meaning that its stock price is 139% less volatile than the S&P 500. Comparatively, Graybug Vision has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500.

Profitability

This table compares Eliem Therapeutics and Graybug Vision’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
Graybug Vision	N/A	-77.61%	-71.34%

Earnings and Valuation

This table compares Eliem Therapeutics and Graybug Vision”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12 million	($0.53)	-20.75
Graybug Vision	$426.96 million	0.00	-$35.60 million	($24.23)	-0.03

Eliem Therapeutics has higher earnings, but lower revenue than Graybug Vision. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks.

Summary

Eliem Therapeutics beats Graybug Vision on 5 of the 9 factors compared between the two stocks.

About Eliem Therapeutics

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

About Graybug Vision

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.